Skip to main content
. 2019 Jan 24;5(1):e000763. doi: 10.1136/rmdopen-2018-000763

Figure 4.

Figure 4

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular events; RCTs, randomised controlled trials.